

Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound represented by formula

(1):

Formula 1



wherein

R¹, R² and R⁵ are each independently selected from a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group which may be substituted with one or more halogen atoms and a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms;

R₂ selected from the group consisting of halogen atom, a C₁-C₆ alkyl group which is substituted with one or more halogen atoms and a C₁-C₆ alkoxy group which is substituted with one or more halogen atoms;

R³ and R⁴ are each independently selected from a hydrogen atom, a halogen atom, -NR^fR^g, -CONR^fR^g, -a C₁-C₆ alkoxy group, a C₁-C₆ alkyl group and -T-(CH₂)_k-V, wherein the alkyl group and the alkoxy group may be substituted with one or more substituents selected from a hydroxyl group, a C₁-C₆ alkoxy group, a halogen atom and -NR^fR^g;
wherein

Re is selected from a hydrogen atom and C₁-C₆ alkyl, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a C₁-C₆ alkoxy group, a halogen atom and -NR^hRⁱ,

R^f and R^g are each independently selected from a hydrogen atom, C₁-C₆ alkyl group and C₁-C₆ alkylcarbonyl group, wherein the alkyl group and the alkylcarbonyl group may be substituted with one to three substituents selected from a hydroxyl group, a C₁-C₆ alkoxy group, a halogen atom and -NR^hRⁱ,

R^h and Rⁱ are each independently selected from a hydrogen atom and C₁-C₆ alkyl group, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a halogen atom and a C₁-C₆ alkoxy group, or

R^f and R^g, and R^h and Rⁱ together with a nitrogen atom to which they

are attached may form a 4- to

7-heterocycle, wherein the heterocycle may be substituted with a C₁-C₆ alkyl group,

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from the group consisting of

-NR_xR_y,

-C(=O)R_z, -OR_z and a C₁-C₆ alkyl group, or V is -NRaRb, -CONRaRb,

-OC(=O)NRaRb, -SO₂NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd,

-C(=O)ORd, -S(=O)_m-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc,

-N(Ra)SO₂Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -C(=O)Rc;

R⁶ and R⁷ are each independently selected from a hydrogen atom and a halogen atom;

Z¹ and Z² are each independently selected from a hydrogen atom, a hydroxyl group and -O(CHR¹¹)OC(=O)R¹²;


wherein

R¹¹ is a hydrogen atom or a C₁-C₆ alkyl group;

R¹² is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C₁-C₆ alkyl group, a mono- or di(C₁-C₆ alkyl)amino C₁-C₆ alkyl group, an amino C₁-C₆ alkylamino group or a mono- or di(C₁-C₆ alkyl)-amino C₁-C₆ alkylamino group;

Q is a group of

Formula 2



wherein

Y¹ is selected from the group consisting of a hydrogen atom, a halogen atom, and a C₂-C₆ alkenyl group;

Wherein

Q is optionally substituted by at least one substituents W, where W is

-NRaRb,

-N=C(-Rc)NRaRb, -N(-Ra)C(=O)NRa'Rb' or -N(-Ra)C(=O)Rc;

Ra, Ra', Rb, Rb', Rc, and Rd are each independently selected from the group consisting of a hydrogen atom, a C₁-C₁₀ alkyl group, a C₃-C₈ cycloalkyl group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, -[(C₁-C₆ alkylene)-O]_n-(C₁-C₃ alkyl),

a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a C₁-C₃ alkyl group);

Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a C₁-C₆ alkyl group;

Ra, Ra', Rb, Rb', Rc, and Rd each may be substituted with one to three same or different substituents selected from Y³;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

Y³ is a halogen atom, -NR_xR_y, -C(=O)OR_z, -C(=O)R_z, -OR_z, -C(=O)NR_xR_y, -OC(=O)NR_xR_y, -SO₂NR_xR_y, -N(-R_x)C(=O)NR_x'R_y', -N(-R_x)C(=O)OR_z, -S-R_z, -SO-R_z, -SO₂-R_z, -OC(=O)R_z, -N(R_x)C(=O)R_z, -C(=NOR_z)NR_x'R_y', -C(=NR_x)NR_x'R_y', -C(=NOR_x)R_z, -[O-(C₁-C₆ alkylene)]_n-O(C₁-C₃ alkyl), -N(-R_x)-(C₁-C₆ alkylene)-O(C₁-C₃ alkyl), -C(=O)R_z, a C₁-C₆ alkyl group, a C₂-C₈ alkenyl group, a C₂-C₈ alkynyl group, an aryl group or a heteroaryl group;


R_x, R_x', R_y, R_y' and R_z are each independently selected from a hydrogen atom and a C₁-C₄ alkyl group;

R_x and R_y, R_x and R_x', R_x and R_z, and R_z and R_x' may form a saturated or unsaturated 5-to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups; a pharmaceutically acceptable salt thereof.

2. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R^2 is selected from a halogen atom, a trifluoromethyl group and a trifluoromethoxy group.

3. (Previously Presented) The compound of claim 2, a pharmaceutically acceptable salt thereof, wherein Q is a group of the formula selected from

Formula 3



which may be substituted with one to three same or different substituents W.

Claims 4-5. (Cancelled)

6. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl group;

R⁶ and R⁷ are hydrogen atoms; and

Z¹ and Z² are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Previously Presented) The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein

R³ and R⁴ are each independently selected from a hydrogen atom, a halogen atom, a C₁-C₆ alkyl group which may be substituted with one or more hydroxyl groups or halogen atoms, a C₁-C₆ alkoxy group which may be substituted with one or more halogen atoms, and -T-(CH₂)_k-V;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group, C₁-C₆ alkyl group, C₁-C₆ alkoxy group and C₁-C₆ alkylcarbonyl group.

8. (Previously Presented) A compound or a pharmaceutically acceptable salt thereof of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Previously Presented) A pharmaceutical composition

comprising a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.

10. (Previously Presented) An Raf inhibitor or an angiogenesis inhibitor comprising a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.

11. (Previously Presented) A therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound or a pharmaceutically acceptable salt thereof of claim 1 as an active ingredient.

Claims 12-13. (Cancelled)